NCT02308553 - Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2015

Primary Completion Date

October 17, 2019

Study Completion Date

November 30, 2019

Conditions

Cutaneous Malignant Melanoma

Interventions

DRUG

Nintedanib

Nintedanib (150 mg or 200 mg BID)

DRUG

Nintedanib-Placebo

Placebo (150 mg or 200 mg BID)

DRUG

Paclitaxel

Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)

Trial Locations (10)

Elbeklinikum Buxtehude, Buxtehude

Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck

University Hospital Essen, Essen

University Hospital Münster, Münster

Fachklinik Hornheide, Münster

Universitätsklinikum des Saarlandes, Homburg

Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen

National Centre for Tumour Diseases (NCT), Heidelberg

University Hospital München, München

SRH Wald-Klinikum Gera, Gera